Skip to main content
Top
Published in: Inflammation 4/2013

01-08-2013

The Detection of Vascular Endothelial Growth Factor in Serum of Patients with Hemorrhagic Fever with Renal Syndrome

Authors: Man Li, Yuqiang Ji, Yanying Dong, Yan Zhou, Huixun Ren, Ming Xie

Published in: Inflammation | Issue 4/2013

Login to get access

Abstract

Hemorrhagic fever with renal syndrome (HFRS) is an acute infectious disease characterized by endothelial cell dysfunction, which results in plasma exosmosis, hyperpermeability, and sometimes hemorrhages. As one of the vascular permeability cytokines, vascular endothelial growth factor (VEGF) might mediate the hyperpermeability caused by HFRS. In the present study, the levels of serum VEGF were measured by competitive inhibition ELISA. We found variable but persistently elevated levels of VEGF throughout the various stages and types of HFRS disease, which suggested that the levels of VEGF were closely correlated to the progression of HFRS. Moreover, elevated levels of VEGF have correlation with the severity and degree of kidney damage. Therefore, to study the relationship between levels of VEGF and disease severity of patients with HFRS is helpful to clarify the pathogenesis of HFRS.
Literature
1.
go back to reference Jonsson, C.B., L.T.M. Figueiredo, and O. Vapalahti. 2010. A global perspective on Hantavirus ecology, epidemiology, and disease. Clin Microbiol Rev 23: 412–441.PubMedCrossRef Jonsson, C.B., L.T.M. Figueiredo, and O. Vapalahti. 2010. A global perspective on Hantavirus ecology, epidemiology, and disease. Clin Microbiol Rev 23: 412–441.PubMedCrossRef
2.
go back to reference Hooper, J.W., T. Larsen, D.M. Custer, and C.S. Schmaljohn. 2001. A lethal disease model for Hantavirus pulmonary syndrome. Virology 289: 6–14.PubMedCrossRef Hooper, J.W., T. Larsen, D.M. Custer, and C.S. Schmaljohn. 2001. A lethal disease model for Hantavirus pulmonary syndrome. Virology 289: 6–14.PubMedCrossRef
3.
go back to reference Klingstrom, J., A. Plyusnin, A. Vaheri, and A. Lundkvist. 2002. Wild-type Puumala Hantavirus infection induces cytokines, C-reactive protein, creatinine, and nitric oxide in cynomolgus macaques. J Virol 76: 444–449.PubMedCrossRef Klingstrom, J., A. Plyusnin, A. Vaheri, and A. Lundkvist. 2002. Wild-type Puumala Hantavirus infection induces cytokines, C-reactive protein, creatinine, and nitric oxide in cynomolgus macaques. J Virol 76: 444–449.PubMedCrossRef
4.
go back to reference Wahl Jensen, V., J. Chapman, L. Asher, R. Fisher, M. Zimmerman, T. Larsen, and J.W. Hooper. 2007. Temporal analysis of Andes virus and Sin Nombre virus infections of Syrian hamsters. J Virol 81: 7449–7462.PubMedCrossRef Wahl Jensen, V., J. Chapman, L. Asher, R. Fisher, M. Zimmerman, T. Larsen, and J.W. Hooper. 2007. Temporal analysis of Andes virus and Sin Nombre virus infections of Syrian hamsters. J Virol 81: 7449–7462.PubMedCrossRef
5.
go back to reference Schmaljohn, C., and B. Hjelle. 1999. Hantaviruses: A global disease problem. Emerg Infect Dis 3: 95–104.CrossRef Schmaljohn, C., and B. Hjelle. 1999. Hantaviruses: A global disease problem. Emerg Infect Dis 3: 95–104.CrossRef
6.
go back to reference Gorbunova, E.E., I.N. Gavrilovskaya, T. Pepini, and E.R. Mackow. 2011. VEGFR2 and Src kinase inhibitors suppress Andes Virus-induced endothelial cell permeability. J Virol 85: 2296–2303.PubMedCrossRef Gorbunova, E.E., I.N. Gavrilovskaya, T. Pepini, and E.R. Mackow. 2011. VEGFR2 and Src kinase inhibitors suppress Andes Virus-induced endothelial cell permeability. J Virol 85: 2296–2303.PubMedCrossRef
7.
go back to reference Gavrilovskaya, I.N., E.E. Gorbunova, N.A. Mackow, and E.R. Mackow. 2008. Hantaviruses direct endothelial cell permeability by sensitizing cells to the vascular permeability factor VEGF, while angiopoietin 1 and sphingosine 1-phosphate inhibit Hantavirus-directed permeability. J Virol 82: 5797–5806.PubMedCrossRef Gavrilovskaya, I.N., E.E. Gorbunova, N.A. Mackow, and E.R. Mackow. 2008. Hantaviruses direct endothelial cell permeability by sensitizing cells to the vascular permeability factor VEGF, while angiopoietin 1 and sphingosine 1-phosphate inhibit Hantavirus-directed permeability. J Virol 82: 5797–5806.PubMedCrossRef
8.
go back to reference Xie, M., P. Chen, L. He, B. Qi, P. Wang, X. Wang, and H. Ren. 2009. The detection of sLFA-3 in plasma of patients with hemorrhagic fever with renal syndrome. Clin Exp Med 9: 67–71.PubMedCrossRef Xie, M., P. Chen, L. He, B. Qi, P. Wang, X. Wang, and H. Ren. 2009. The detection of sLFA-3 in plasma of patients with hemorrhagic fever with renal syndrome. Clin Exp Med 9: 67–71.PubMedCrossRef
9.
go back to reference Khaiboullina, S.F., D.M. Netski, P. Krumpe, and S.C. St Jeor. 2000. Effects of tumor necrosis factor alpha on Sin Nombre virus infection in vitro. J Virol 74: 11966–11971.PubMedCrossRef Khaiboullina, S.F., D.M. Netski, P. Krumpe, and S.C. St Jeor. 2000. Effects of tumor necrosis factor alpha on Sin Nombre virus infection in vitro. J Virol 74: 11966–11971.PubMedCrossRef
10.
go back to reference Sundstrom, J.B., L.K. McMullan, C.F. Spiropoulou, W.C. Hooper, A.A. Ansari, C.J. Peters, and P.E. Rollin. 2001. Hantavirus infection induces the expression of RANTES and IP-10 without causing increased permeability in human lung microvascular endothelial cells. J Virol 75: 6070–6085.PubMedCrossRef Sundstrom, J.B., L.K. McMullan, C.F. Spiropoulou, W.C. Hooper, A.A. Ansari, C.J. Peters, and P.E. Rollin. 2001. Hantavirus infection induces the expression of RANTES and IP-10 without causing increased permeability in human lung microvascular endothelial cells. J Virol 75: 6070–6085.PubMedCrossRef
11.
go back to reference Zaki, S., P. Greer, L. Coffield, C. Goldsmith, K. Nolte, K. Foucar, R. Feddersen, R. Zumwalt, G. Miller, P. Rollin, T. Ksiazek, S. Nichol, and C. Peters. 1995. Hantavirus pulmonary syndrome: pathogenesis of an emerging infectious disease. Am J Pathol 146: 552–579.PubMed Zaki, S., P. Greer, L. Coffield, C. Goldsmith, K. Nolte, K. Foucar, R. Feddersen, R. Zumwalt, G. Miller, P. Rollin, T. Ksiazek, S. Nichol, and C. Peters. 1995. Hantavirus pulmonary syndrome: pathogenesis of an emerging infectious disease. Am J Pathol 146: 552–579.PubMed
12.
go back to reference Shrivastava-Ranjan, P., P.E. Rollin, and C.F. Spiropoulou. 2010. Andes virus disrupts the endothelial cell barrier by induction of vascular endothelial growth factor and downregulation of VE-cadherin. J Virol 84: 11227–11234.PubMedCrossRef Shrivastava-Ranjan, P., P.E. Rollin, and C.F. Spiropoulou. 2010. Andes virus disrupts the endothelial cell barrier by induction of vascular endothelial growth factor and downregulation of VE-cadherin. J Virol 84: 11227–11234.PubMedCrossRef
13.
go back to reference Mackow, E.R., and I.N. Gavrilovskaya. 2009. Hantavirus regulation of endothelial cell functions. Thromb Haemost 102(6): 1030–1041.PubMed Mackow, E.R., and I.N. Gavrilovskaya. 2009. Hantavirus regulation of endothelial cell functions. Thromb Haemost 102(6): 1030–1041.PubMed
14.
go back to reference Weis, M.S., and D.A. Cheresh. 2005. Pathophysiological consequences of VEGF induced vascular permeability. Nature 437(7058): 497–504.PubMedCrossRef Weis, M.S., and D.A. Cheresh. 2005. Pathophysiological consequences of VEGF induced vascular permeability. Nature 437(7058): 497–504.PubMedCrossRef
15.
go back to reference Lampugnani, M.G., F. Orsenigo, M.C. Gagliani, C. Tacchetti, and E. Dejana. 2006. Vascular endothelial cadherin controls VEGFR-2 internalization and signaling from intracellular compartments. J Cell Biol 174: 593–604.PubMedCrossRef Lampugnani, M.G., F. Orsenigo, M.C. Gagliani, C. Tacchetti, and E. Dejana. 2006. Vascular endothelial cadherin controls VEGFR-2 internalization and signaling from intracellular compartments. J Cell Biol 174: 593–604.PubMedCrossRef
16.
go back to reference Yanagihara, R., and D.J. Silverman. 1990. Experimental infection of human vascular endothelial cells by pathogenic and nonpathogenic hantaviruses. Arch Virol 111: 281–6.PubMedCrossRef Yanagihara, R., and D.J. Silverman. 1990. Experimental infection of human vascular endothelial cells by pathogenic and nonpathogenic hantaviruses. Arch Virol 111: 281–6.PubMedCrossRef
17.
go back to reference Bustamante, E.A., H. Levy, and S.Q. Simpson. 1997. Pleural fluid characteristics in Hantavirus pulmonary syndrome. Chest 112: 1133–1136.PubMedCrossRef Bustamante, E.A., H. Levy, and S.Q. Simpson. 1997. Pleural fluid characteristics in Hantavirus pulmonary syndrome. Chest 112: 1133–1136.PubMedCrossRef
18.
go back to reference Nolte, K.B., R.M. Feddersen, K. Foucar, S.R. Zaki, F.T. Koster, D. Madar, T.L. Merlin, P.J. McFeeley, E.T. Umland, and R.E. Zumwalt. 1995. Hantavirus pulmonary syndrome in the United States: A pathological description of a disease caused by a new agent. Hum Pathol 26: 110–120.PubMedCrossRef Nolte, K.B., R.M. Feddersen, K. Foucar, S.R. Zaki, F.T. Koster, D. Madar, T.L. Merlin, P.J. McFeeley, E.T. Umland, and R.E. Zumwalt. 1995. Hantavirus pulmonary syndrome in the United States: A pathological description of a disease caused by a new agent. Hum Pathol 26: 110–120.PubMedCrossRef
19.
go back to reference Pensiero, M.N., J.B. Sharefkin, C.W. Dieffenbach, and J. Hay. 1992. Hantaan virus infection of human endothelial cells. J Virol 66: 5929–36.PubMed Pensiero, M.N., J.B. Sharefkin, C.W. Dieffenbach, and J. Hay. 1992. Hantaan virus infection of human endothelial cells. J Virol 66: 5929–36.PubMed
20.
go back to reference Kanerva, M., J. Mustonen, and A. Vaheri. 1998. Pathogenesis of Puumala and other Hantavirus infections. Rev Med Virol 8: 67–86.PubMedCrossRef Kanerva, M., J. Mustonen, and A. Vaheri. 1998. Pathogenesis of Puumala and other Hantavirus infections. Rev Med Virol 8: 67–86.PubMedCrossRef
21.
go back to reference Chang, B., M. Crowley, M. Campen, and F. Koster. 2007. Hantavirus cardiopulmonary syndrome. Semin Respir Crit Care Med 28: 193–200.PubMedCrossRef Chang, B., M. Crowley, M. Campen, and F. Koster. 2007. Hantavirus cardiopulmonary syndrome. Semin Respir Crit Care Med 28: 193–200.PubMedCrossRef
22.
go back to reference Hallin, G.W., et al. 1996. Cardiopulmonary manifestations of Hantavirus pulmonary syndrome. Crit Care Med 24: 252–258.PubMedCrossRef Hallin, G.W., et al. 1996. Cardiopulmonary manifestations of Hantavirus pulmonary syndrome. Crit Care Med 24: 252–258.PubMedCrossRef
23.
go back to reference Taddei, A., C. Giampietro, A. Conti, F. Orsenigo, F. Breviario, V. Pirazzoli, M. Potente, C. Daly, S. Dimmeler, and E. Dejana. 2008. Endothelial adherens junctions control tight junctions by VE-cadherin-mediated upregulation of claudin-5. Nat Cell Biol 10: 923–934.PubMedCrossRef Taddei, A., C. Giampietro, A. Conti, F. Orsenigo, F. Breviario, V. Pirazzoli, M. Potente, C. Daly, S. Dimmeler, and E. Dejana. 2008. Endothelial adherens junctions control tight junctions by VE-cadherin-mediated upregulation of claudin-5. Nat Cell Biol 10: 923–934.PubMedCrossRef
24.
go back to reference Venkiteswaran, K., K. Xiao, S. Summers, C.C. Calkins, P.A. Vincent, K. Pumiglia, and A.P. Kowalczyk. 2002. Regulation of endothelial barrier function and growth by VE-cadherin, plakoglobin, and beta-catenin. Am J Physiol Cell Physiol 283: C811–821.PubMedCrossRef Venkiteswaran, K., K. Xiao, S. Summers, C.C. Calkins, P.A. Vincent, K. Pumiglia, and A.P. Kowalczyk. 2002. Regulation of endothelial barrier function and growth by VE-cadherin, plakoglobin, and beta-catenin. Am J Physiol Cell Physiol 283: C811–821.PubMedCrossRef
25.
go back to reference Vincent, P.A., K. Xiao, K.M. Buckley, and A.P. Kowalczyk. 2004. VEcadherin: adhesion at arm’s length. Am J Physiol Cell Physiol 286: C987–C997.PubMedCrossRef Vincent, P.A., K. Xiao, K.M. Buckley, and A.P. Kowalczyk. 2004. VEcadherin: adhesion at arm’s length. Am J Physiol Cell Physiol 286: C987–C997.PubMedCrossRef
26.
go back to reference Gavard, J., and J.S. Gutkind. 2006. VEGF controls endothelial cell permeability by promoting the beta-arrestin-dependent endocytosis of VE-cadherin. Nat Cell Biol 8: 1223–1234.PubMedCrossRef Gavard, J., and J.S. Gutkind. 2006. VEGF controls endothelial cell permeability by promoting the beta-arrestin-dependent endocytosis of VE-cadherin. Nat Cell Biol 8: 1223–1234.PubMedCrossRef
27.
go back to reference Lampugnani, M.G., and E. Dejana. 2007. The control of endothelial cell functions by adherens junctions. Novartis Found Symp 283(4–17): 238–241. Lampugnani, M.G., and E. Dejana. 2007. The control of endothelial cell functions by adherens junctions. Novartis Found Symp 283(4–17): 238–241.
28.
go back to reference Olsson, A.K., et al. 2006. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 7: 359–371.PubMedCrossRef Olsson, A.K., et al. 2006. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 7: 359–371.PubMedCrossRef
29.
go back to reference Wallez, Y., et al. 2006. Angiogenesis: The VE-cadherin switch. Trends Cardiovasc Med 16: 55–5930.PubMedCrossRef Wallez, Y., et al. 2006. Angiogenesis: The VE-cadherin switch. Trends Cardiovasc Med 16: 55–5930.PubMedCrossRef
30.
go back to reference Bao, P., A. Kodra, M. Tomic-Canic, et al. 2009. The role of vascular endothelial growth factor in wound healing. J Surg Res 153: 347–358.PubMedCrossRef Bao, P., A. Kodra, M. Tomic-Canic, et al. 2009. The role of vascular endothelial growth factor in wound healing. J Surg Res 153: 347–358.PubMedCrossRef
32.
33.
go back to reference Lee, C.G., B. Ma, S. Takyar, F. Ahangari, C. DelaCruz, C.H. He, and J.A. Elias. 2011. Studies of vascular endothelial growth factor in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc 8: 512–515.PubMedCrossRef Lee, C.G., B. Ma, S. Takyar, F. Ahangari, C. DelaCruz, C.H. He, and J.A. Elias. 2011. Studies of vascular endothelial growth factor in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc 8: 512–515.PubMedCrossRef
34.
go back to reference Coenjaerts, F.J., M. van der Flier, P.N.M. Mwinzi, A.E. Brouwer, et al. 2004. Intrathecal production and secretion of vascular endothelial growth factor during cryptococcal meningitis. J Infect Dis 190: 1310–7.PubMedCrossRef Coenjaerts, F.J., M. van der Flier, P.N.M. Mwinzi, A.E. Brouwer, et al. 2004. Intrathecal production and secretion of vascular endothelial growth factor during cryptococcal meningitis. J Infect Dis 190: 1310–7.PubMedCrossRef
35.
go back to reference Oranskiy, S.P., L.N. Yeliseyeva, A.V. Tsanaeva, and N.V. Zaytseva. 2012. Body composition and serum levels of adiponectin, vascular endothelial growth factor, and interleukin-6 in patients with rheumatoid arthritis. Croat Med J 53: 350–6.PubMedCrossRef Oranskiy, S.P., L.N. Yeliseyeva, A.V. Tsanaeva, and N.V. Zaytseva. 2012. Body composition and serum levels of adiponectin, vascular endothelial growth factor, and interleukin-6 in patients with rheumatoid arthritis. Croat Med J 53: 350–6.PubMedCrossRef
36.
go back to reference Paine, S.K., A. Basu, L.K. Mondal, A. Sen, et al. 2012. Association of vascular endothelial growth factor, transforming growth factor beta, and interferon gamma gene polymorphisms with proliferative diabetic retinopathy in patients with type 2 diabetes. Molecular Vision 18: 2749–2757.PubMed Paine, S.K., A. Basu, L.K. Mondal, A. Sen, et al. 2012. Association of vascular endothelial growth factor, transforming growth factor beta, and interferon gamma gene polymorphisms with proliferative diabetic retinopathy in patients with type 2 diabetes. Molecular Vision 18: 2749–2757.PubMed
37.
go back to reference Matsune, S. 2012. Allergic rhinitis and vascular endothelial growth factor. J Nippon Med Sch 79(3): 170–175.PubMedCrossRef Matsune, S. 2012. Allergic rhinitis and vascular endothelial growth factor. J Nippon Med Sch 79(3): 170–175.PubMedCrossRef
Metadata
Title
The Detection of Vascular Endothelial Growth Factor in Serum of Patients with Hemorrhagic Fever with Renal Syndrome
Authors
Man Li
Yuqiang Ji
Yanying Dong
Yan Zhou
Huixun Ren
Ming Xie
Publication date
01-08-2013
Publisher
Springer US
Published in
Inflammation / Issue 4/2013
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-013-9627-x

Other articles of this Issue 4/2013

Inflammation 4/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine